News

Conference Coverage

Addition of Relacorilant to Nab-Paclitaxel Improves OS in Recurrent Platinum–Resistant Ovarian Cancer

06/06/2022

OS data from a phase 2 clinical trial confirm the benefit of adding intermittent relacorilant to nab-paclitaxel for patients with ovarian cancer, especially those without primary platinum-refractory disease.

OS data from a phase 2 clinical...

06/06/2022

Oncology

News

Olaparib and Cediranib vs Chemotherapy for Platinum-Sensitive Ovarian Cancer

04/14/2022

John Otrompke , BA, JD;

Olaparib and cediranib each demonstrated a clinical advantage in PFS over chemotherapy in patients with BRCA–mutated ovarian cancer; however, combination olaparib-cediranib did not improve PFS vs chemotherapy in the patient population as a...

Olaparib and cediranib each...

04/14/2022

Oncology

News

Rucaparib Provides PFS Benefit vs Chemotherapy for BRCA1– or BRCA2–Mutant Ovarian Cancer

04/14/2022

John Otrompke , BA, JD;

Among patients with BRCA1– or BRCA2–mutant ovarian carcinoma, treatment with rucaparib was associated with improved PFS vs standard chemotherapy in the phase 3 ARIEL4 trial.

Among patients with BRCA1– or...

04/14/2022

Oncology

News

Pembrolizumab Found Beneficial in Persistent, Metastatic, or Recurrent Cervical Cancer

03/29/2022

Experts at the SGO Annual Meeting on Women's Oncology revealed adding pembrolizumab to chemotherapy ± bevacizumab provides statistically significant, clinically meaningful OS and PFS improvements in women with persistent, recurrent, or...

Experts at the SGO Annual...

03/29/2022

Oncology

News

Administering Gonadotropin-Releasing Analogs During Chemo in Premenopausal Women With BC Reduces Ovarian Impairment

02/24/2022

Clinical trial results reveal gonadotropin-releasing hormone analogs (GnRHa) promote the recovery of ovarian function and reduces the risk of premature ovarian insufficiency (POI) in premenopausal women with breast cancer.

Clinical trial results reveal...

02/24/2022

Oncology

Conference Insider

The Role of CD10 Expression in enMSC on the Progression of EAC

06/03/2021

Experts determine the Role of CD10 expression in endometriosis-associated mesenchymal stem cells on the progression of endometriosis-associated carcinoma, presented at the 2021 ASCO Annual Meeting.

Experts determine the Role of...

06/03/2021

Oncology

News

Upfront MGPT Improves Lynch Syndrome Diagnosis in Patients With Endometrial Cancer

05/29/2021

According to data being presented at ASCO 2021, the use of upfront MGPT in patients with endometrial cancer has improved the detection of Lynch syndrome among this population.

According to data being...

05/29/2021

Oncology

News

Experts Discourage Intensive Follow-Up of Patients Treated for Endometrial Cancer

05/25/2021

According to study findings presented at the 2021 ASCO Annual Meeting, the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer should be discouraged.

According to study findings...

05/25/2021

Oncology

News

Endometrial Cancer Incidence Tied to Obesity in Young Adult Women

05/25/2021

At the 2021 ASCO Annual Meeting, researchers presented data from a study evaluating trends in endometrial cancer incidence and its relationship to obesity in the United States.

At the 2021 ASCO Annual Meeting,...

05/25/2021

Oncology

News

FDA Approves Dostarlimab-gxly for Adults With dMMR Endometrial Cancer

04/22/2021

Hina M. Porcelli ;

The FDA has approved dostarlimab-gxly for the treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing therapy.

The FDA has approved...

04/22/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology